Division of Pfizer Inc.
Latest From Apollon Inc.
Not all initial public offerings are taken up, even in the best of funding years. Of the 54 life sciences IPOs registered in 1997, 11 (20%) were withdrawn because of pricing issues or lack of interest.
Life sciences investors pumped around $15 billion into 175 biotech, medtech and diagnostics firms that went public during the 2014–16 IPO window. To understand what may be in store for those firms and their backers, In Vivo reexamines the fate of a previous generation of companies, the IPO Class of 1997.
- Therapeutic Areas
- Infectious & Viral Diseases
- North America
- Parent & Subsidiaries
- Pfizer Inc.
- Senior Management
Vincent Zurawski, Jr., Pres. & CEO
Mark J Newman, PhD, Dir., Immunobiology
- Contact Info
Phone: (610) 647-9452
One Great Valley Parkway
Malvern, PA 19355-1307
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.